Takeda Reports First Patients Dosing in P-I/II Study of Novavax’s COVID-19 Vaccine Candidate in Japan

Shots:

• Takeda is providing rapid & sustained access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. Earlier, Takeda has completed enrollment in the P-I/II study of TAK-919 in Japan
• The studies are designed to include 200 healthy Japanese adults followed by 12mos. after the second vaccination with primary results expected in CY2021. Takeda plans to start distributing TAK-919 in the H1’21 and TAK-019 in late 2021
• Takeda to receive a manufacturing technology transfer from Novavax and will be responsible for the development & commercialization of over 250M doses of TAK-019 and also import & distribute 50M doses of TAK-919 with Moderna and MHLW

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Pharmaceutical Technology